{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T21:23:26Z","timestamp":1789680206877,"version":"4.0.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s10557-025-07801-2","type":"journal-article","created":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T09:50:52Z","timestamp":1761558652000},"page":"1061-1070","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Ivabradine Versus Up-titrated Bisoprolol for Persistent Tachycardia After Primary PCI in Anterior STEMI: A Single-center, Open-label, Pragmatic RCT"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-5604-3524","authenticated-orcid":false,"given":"Jianqiang","family":"Meng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8083-0675","authenticated-orcid":false,"given":"Hailiang","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6147-2085","authenticated-orcid":false,"given":"Dewen","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1994-7922","authenticated-orcid":false,"given":"Yuanben","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4008-8872","authenticated-orcid":false,"given":"Zhenhua","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,27]]},"reference":[{"key":"7801_CR1","unstructured":"Jing J, Li X, Li Q, et al. ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective analysis of hospital data [J]. Lancet. 2015."},{"key":"7801_CR2","volume-title":"Case Fatality Rate of Patients with Acute Myocardial Infarction in 253 Chest Pain Centers - China, 2019\u20132020 [J]","author":"Z Zheng","year":"2022","unstructured":"Zheng Z, Long W, Liu Z, et al. Case Fatality Rate of Patients with Acute Myocardial Infarction in 253 Chest Pain Centers - China, 2019\u20132020 [J]. China CDC weekly; 2022."},{"key":"7801_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2011.06.007","author":"D Planer","year":"2011","unstructured":"Planer D, Mehran R, Witzenbichler B, et al. Prognostic utility of left ventricular end-diastolic pressure in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Am J Cardiol. 2011. https:\/\/doi.org\/10.1016\/j.amjcard.2011.06.007.","journal-title":"Am J Cardiol"},{"key":"7801_CR4","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2024-097434","author":"X Pan","year":"2025","unstructured":"Pan X, Du W, Liu Z. Poor clinical outcome despite successful recanalisation in patients with acute myocardial infarction undergoing direct percutaneous coronary intervention: a retrospective cohort study. BMJ Open. 2025. https:\/\/doi.org\/10.1136\/bmjopen-2024-097434.","journal-title":"BMJ Open"},{"key":"7801_CR5","doi-asserted-by":"crossref","unstructured":"Buske M, Hj F, Jobs A et al. Management of acute coronary syndrome: ESC guidelines 2023. Herz, 2024.","DOI":"10.1007\/s00059-023-05222-1"},{"key":"7801_CR6","volume-title":"Beta-blocker therapy in patients with acute myocardial infarction: not all patients need it [J]","author":"Joo Sj","year":"2023","unstructured":"Joo Sj. Beta-blocker therapy in patients with acute myocardial infarction: not all patients need it [J]. Acute Crit Care; 2023."},{"key":"7801_CR7","unstructured":"Dondo Tb, Hall M, Rm W, et al. \u03b2-Blockers and Mortality After Acute Myocardial Infarction in Patients Without Heart Failure or Ventricular Dysfunction [J]. J Am Coll Cardiol. 2017."},{"key":"7801_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahjo.2022.100158","author":"Ja. Borovac","year":"2022","unstructured":"Borovac Ja., Kowalski M, Poklepovic Pericic T, et al. Clinical use of ivabradine in the acute coronary syndrome: a systematic review and narrative synthesis of current evidence. American Heart Journal Plus: Cardiology Research and Practice. 2022. https:\/\/doi.org\/10.1016\/j.ahjo.2022.100158.","journal-title":"American Heart Journal Plus: Cardiology Research and Practice"},{"key":"7801_CR9","doi-asserted-by":"crossref","unstructured":"Thygesen K, Alpert JS, Jaffe AS et al. Fourth universal definition of myocardial infarction (2018). Eur Heart J 2019.","DOI":"10.1093\/eurheartj\/ehy856"},{"key":"7801_CR10","doi-asserted-by":"crossref","unstructured":"Levey AS, Stevens LA, Schmid CH. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009.","DOI":"10.7326\/0003-4819-150-9-200905050-00006"},{"key":"7801_CR11","doi-asserted-by":"publisher","DOI":"10.1093\/ehjacc\/zuad107","volume-title":"2023 ESC Guidelines for the management of acute coronary syndromes [J]","author":"X Rossello","year":"2024","unstructured":"Byrne Ra, Rossello X, Jj C, et al. 2023 ESC Guidelines for the management of acute coronary syndromes [J]. Giornale italiano di cardiologia; 2024."},{"key":"7801_CR12","unstructured":"Rao Sv, O\u2019Donoghue Ml., Ruel M, et al. 2025 ACC\/AHA\/ACEP\/NAEMSP\/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2025."},{"key":"7801_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s44156-022-00006-5","author":"L Corbett","year":"2022","unstructured":"Corbett L, Forster J, Gamlin W, et al. A practical guideline for performing a comprehensive transthoracic echocardiogram in the congenital heart disease patient: consensus recommendations from the British society of echocardiography. Echo Res Pract. 2022. https:\/\/doi.org\/10.1186\/s44156-022-00006-5.","journal-title":"Echo Res Pract"},{"key":"7801_CR14","doi-asserted-by":"publisher","DOI":"10.1530\/ERP-20-0026","author":"S Robinson","year":"2020","unstructured":"Robinson S, Rana B, Oxborough D, et al. A practical guideline for performing a comprehensive transthoracic echocardiogram in adults: the British society of echocardiography minimum dataset. Echo Res Pract. 2020. https:\/\/doi.org\/10.1530\/ERP-20-0026.","journal-title":"Echo Res Pract"},{"key":"7801_CR15","doi-asserted-by":"publisher","DOI":"10.1111\/anec.12816","author":"Y Xu","year":"2021","unstructured":"Xu Y, Zhang W, Zhong X, et al. Effect of early use of ivabradine on left ventricular remodeling after primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction: a pilot test. Ann Noninvasive Electrocardiol. 2021. https:\/\/doi.org\/10.1111\/anec.12816.","journal-title":"Ann Noninvasive Electrocardiol"},{"key":"7801_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbalip.2018.08.002","author":"M Anastasius","year":"2018","unstructured":"Anastasius M, Luquain-Costaz C, Kockx M, et al. A critical appraisal of the measurement of serum \u2018cholesterol efflux capacity\u2019 and its use as surrogate marker of risk of cardiovascular disease. Biochimica et Biophysica Acta (BBA). 2018. https:\/\/doi.org\/10.1016\/j.bbalip.2018.08.002.","journal-title":"Biochimica et Biophysica Acta (BBA)"},{"key":"7801_CR17","doi-asserted-by":"crossref","unstructured":"Verma S, Sc B, Jb B, et al. Occurence of First and Recurrent Major Adverse Cardiovascular Events With Liraglutide Treatment Among Patients With Type 2 Diabetes and High Risk of Cardiovascular Events: A Post Hoc Analysis of a Randomized Clinical Trial [J]. JAMA Cardiol. 2019.","DOI":"10.1001\/jamacardio.2019.3080"},{"key":"7801_CR18","volume-title":"Reassessing Ivabradine: Potential Benefits and Risks in Atrial Fibrillation Therapy [J]","author":"D Alijanzadeh","year":"2024","unstructured":"Alijanzadeh D, Moghim S, Zarand P, et al. Reassessing Ivabradine: Potential Benefits and Risks in Atrial Fibrillation Therapy [J]. Cardiovasc Drugs Ther; 2024."},{"key":"7801_CR19","volume-title":"The Beta-Blocker Dilemma: Revisiting Their Role in Cardiovascular Disease [J]","author":"M Fordham","year":"2025","unstructured":"Fordham M, Lyubarova R, Sidhu M. The Beta-Blocker Dilemma: Revisiting Their Role in Cardiovascular Disease [J]. Cardiovasc Drugs Ther; 2025."},{"key":"7801_CR20","doi-asserted-by":"crossref","unstructured":"Fordham M, Lyubarova R, Sidhu M. Correction to: the Beta-Blocker dilemma: revisiting their role in cardiovascular disease. Cardiovasc Drugs Ther 2025.","DOI":"10.1007\/s10557-025-07755-5"},{"key":"7801_CR21","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-023-07502-8","author":"N Osataphan","year":"2024","unstructured":"Osataphan N, Udol K, Siriwattana K, et al. Effect of beta-blocker on long-term major cardiovascular events in high atherosclerotic risk population. Cardiovasc Drugs Ther. 2024. https:\/\/doi.org\/10.1007\/s10557-023-07502-8.","journal-title":"Cardiovasc Drugs Ther"},{"key":"7801_CR22","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-023-07448-x","author":"B Sun","year":"2024","unstructured":"Sun B, Wang CY, Chen RR. Clinical efficacy and safety of early intravenous administration of beta-blockers in patients suffering from acute ST-segment elevation myocardial infarction without heart failure undergoing primary percutaneous coronary intervention: a study-level meta-analysis of randomized clinical trials. Cardiovasc Drugs Ther. 2024. https:\/\/doi.org\/10.1007\/s10557-023-07448-x.","journal-title":"Cardiovasc Drugs Ther"},{"key":"7801_CR23","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-024-07610-z","author":"MR Syed","year":"2025","unstructured":"Syed MR, Khan KS, Iman K. Beta-blockers and myocardial infarction: to \u03b2 -block or not to \u03b2 -block. Cardiovasc Drugs Ther. 2025. https:\/\/doi.org\/10.1007\/s10557-024-07610-z.","journal-title":"Cardiovasc Drugs Ther"},{"key":"7801_CR24","doi-asserted-by":"crossref","unstructured":"Tardif JC, O\u2019Meara E, Komajda M et al. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. Eur Heart J 2011.","DOI":"10.1093\/eurheartj\/ehr311"},{"key":"7801_CR25","doi-asserted-by":"crossref","unstructured":"Ceconi C, SB F, JC T et al. Effect of heart rate reduction by ivabradine on left ventricular remodeling in the echocardiographic substudy of BEAUTIFUL. Int J Cardiol. 2011.","DOI":"10.1016\/j.ijcard.2010.10.125"},{"key":"7801_CR26","unstructured":"Cargnoni A, Ceconi C, Stavroula G, et al. Adv Cardiol. 2006."},{"key":"7801_CR27","doi-asserted-by":"crossref","unstructured":"V\u00edtovec J, Spinarov\u00e1 L, Spinar J. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and health related quality of life: results from the SHIFT substudies. Vnitr\u0306n\u00ed l\u00e9kar\u0306stv\u00ed. 2012.","DOI":"10.1016\/S0084-3873(12)00265-9"},{"key":"7801_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61198-1","author":"K Swedberg","year":"2010","unstructured":"Swedberg K, Komajda M, B\u00f6hm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010. https:\/\/doi.org\/10.1016\/S0140-6736(10)61198-1.","journal-title":"Lancet"},{"key":"7801_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61259-7","author":"M B\u00f6hm","year":"2010","unstructured":"B\u00f6hm M, Swedberg K, Komajda M, et al. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial [J]. Lancet. 2010. https:\/\/doi.org\/10.1016\/S0140-6736(10)61259-7.","journal-title":"Lancet"},{"key":"7801_CR30","doi-asserted-by":"crossref","unstructured":"Fox K, Ford I, Pg S et al. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial [J]. Lancet, 2008.","DOI":"10.1016\/S0140-6736(08)61170-8"},{"key":"7801_CR31","doi-asserted-by":"crossref","unstructured":"Hidalgo FJ, Anguita M, Jc C et al. Effect of early treatment with ivabradine combined with beta-blockers versus beta-blockers alone in patients hospitalised with heart failure and reduced left ventricular ejection fraction (ETHIC-AHF): A randomised study. Int J Cardiol. 2016.","DOI":"10.23937\/2378-2951\/1410093"},{"key":"7801_CR32","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-016-6678-x","author":"A Giavarini","year":"2016","unstructured":"Giavarini A, de Silva R. The role of ivabradine in the management of angina pectoris. Cardiovasc Drugs Ther. 2016. https:\/\/doi.org\/10.1007\/s10557-016-6678-x.","journal-title":"Cardiovasc Drugs Ther"},{"key":"7801_CR33","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-024-07626-5","author":"A Latif","year":"2024","unstructured":"Latif A, Jia X. Use of early intravenous beta blockers in patients with acute ST-segment elevation myocardial infarction without heart failure-revival or requiem? Cardiovasc Drugs Ther. 2024. https:\/\/doi.org\/10.1007\/s10557-024-07626-5.","journal-title":"Cardiovasc Drugs Ther"},{"key":"7801_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s12871-025-03121-y","author":"L Calabr\u00f2","year":"2025","unstructured":"Calabr\u00f2 L, Pasetto M, Scolletta S, et al. Ivabradine use in critical care: a systematic review and metanalysis of cardiogenic and septic shock patients. BMC Anesthesiol. 2025. https:\/\/doi.org\/10.1186\/s12871-025-03121-y.","journal-title":"BMC Anesthesiol"},{"key":"7801_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s12872-025-04854-x","author":"X Guo","year":"2025","unstructured":"Guo X, Yang W, Cui Y, et al. Long-term safety and efficacy of ivabradine after direct percutaneous coronary intervention in patients with acute myocardial infarction complicated by heart failure: a single-center retrospective study [J]. BMC Cardiovasc Disord. 2025. https:\/\/doi.org\/10.1186\/s12872-025-04854-x.","journal-title":"BMC Cardiovasc Disord"},{"key":"7801_CR36","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehn571","author":"Jc Tardif","year":"2009","unstructured":"Tardif Jc, Ponikowski P, Kahan T. Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial. Eur Heart J. 2009. https:\/\/doi.org\/10.1093\/eurheartj\/ehn571.","journal-title":"Eur Heart J"},{"key":"7801_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2010.10.065","author":"M Tendera","year":"2011","unstructured":"Tendera M, Talajic M, Robertson M, et al. Safety of ivabradine in patients with coronary artery disease and left ventricular systolic dysfunction (from the BEAUTIFUL Holter substudy). Am J Cardiol. 2011. https:\/\/doi.org\/10.1016\/j.amjcard.2010.10.065.","journal-title":"Am J Cardiol"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-025-07801-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-025-07801-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-025-07801-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T05:21:30Z","timestamp":1778649690000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-025-07801-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,27]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["7801"],"URL":"https:\/\/doi.org\/10.1007\/s10557-025-07801-2","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,27]]},"assertion":[{"value":"15 October 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have read and approved the final version of the manuscript and consent to its publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"This study was approved by the Ethics Committee of Shaoxing Central Hospital (approval number:2022-015). The study was conducted in accordance with the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Written informed consent was obtained from all participants.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent To Participate"}},{"value":"The authors declare that they have no conflicts of interest.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}